Wealthfront Advisers
BMRN icon

Wealthfront Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealthfront Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,069
Closed -$288K – 966
2025
Q1 		$288K Buy
+4,069
New +$274K ﹤0.01% 851
2024
Q4 		– Sell
-30,188
Closed -$2.12M – 916
2024
Q3 		$2.12M Sell
30,188
-619
-2% -$51.7K 0.01% 486
2024
Q2 		$2.54M Buy
30,807
+3,619
+13% +$301K 0.01% 430
2024
Q1 		$2.37M Sell
27,188
-2,648
-9% -$237K 0.01% 445
2023
Q4 		$2.88M Buy
29,836
+6,591
+28% +$583K 0.01% 372
2023
Q3 		$2.06M Sell
23,245
-5,763
-20% -$513K 0.01% 418
2023
Q2 		$2.51M Sell
29,008
-15,342
-35% -$1.44M 0.01% 373
2023
Q1 		$4.31M Buy
44,350
+21,347
+93% +$2.21M 0.02% 235
2022
Q4 		$2.38M Buy
23,003
+16,727
+267% +$1.57M 0.01% 364
2022
Q3 		$532K Buy
6,276
+3,620
+136% +$322K ﹤0.01% 588
2022
Q2 		$220K Buy
+2,656
New +$211K ﹤0.01% 744

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthfront Advisers's BMRN Position: Q2 2025 in Review

Wealthfront Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 4,069 shares — an estimated $288K sold.

Wealthfront Advisers first reported a position in BMRN in Q2 2022 and held it in 11 quarters. The position peaked at $4.31M in Q1 2023. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Wealthfront Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Wealthfront Advisers sold 4,069 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $288K.
  • Wealthfront Advisers first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Wealthfront Advisers's BioMarin Pharmaceuticals position peaked at $4.31M in Q1 2023.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Wealthfront Advisers's 13F filing for Q2 2025, filed 31 Jul 2025.